Faculty Collaboration Database

Clinical efficacy of the Abbott Tacrolimus II assay for the IMx. Ann Clin Lab Sci 1999;29(4):299-302

Date

10/21/1999

Pubmed ID

10528829

Scopus ID

2-s2.0-0032704003 (requires institutional sign-in at Scopus site)   4 Citations

Abstract

Monitoring tacrolimus is essential to maintain therapeutic concentrations. Performance of the new Abbott Tacrolimus assay (FK II) was evaluated and compared to the original tacrolimus assay (FK I). 189 trough whole blood samples from transplant cases were included in the study. Samples (n = 117) with FK I concentrations > 5 ng/mL were reanalyzed with the FK II assay. Patient samples (n = 43) that had FK I concentration < 5 ng/mL with apparent mean and range of 3.1 ng/mL and 0.7 to 4.5 ng/mL, respectively, were also reanalyzed with FK II to yield a mean of 5.9 ng/mL with a range of 2.9 to 10.8 ng/mL. Checking for patient compliance, samples (n = 10) with a FK I concentration of 0 ng/mL were re-analyzed. With one exception of a mislabeled cyclosporine sample, all samples (n = 9) showed FK506 levels greater than 2 ng/mL with the FK II assay. The FK II assay was shown to be a clinically efficacious assay, with improved sensitivity and acceptable precision versus the previous FK I assay.

Author List

Cannon RD, Wong SH, Hariharan S, Adams MB, Johnson CP, Roza AM, Pearson ML, Werner CL

Author

Christopher P. Johnson MD Professor in the Surgery department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Adult
Drug Monitoring
Female
Graft Rejection
Humans
Immunosuppressive Agents
Male
Middle Aged
Reagent Kits, Diagnostic
Sensitivity and Specificity
Tacrolimus